SSTR5: Somatostatin receptor type 5
Receptor for somatostatin 28 and to a lesser extent for somatostatin-14.
- Drugs that act on it: 5
- Approved: 2
- In phases 1 to 3: 3
- Sponsors: 4
Who is on it, and how far along
Every drug ChEMBL records acting on SSTR5, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Protein or peptide 4
- Other 1
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- Aspireo Pharmaceuticals Limited120%
- Ipsen120%
- Novartis Pharmaceuticals120%
- Tiburio Therapeutics120%
The landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Somatostatin receptor 5 agonist.| Lanreotide | Approved | Ipsen | Protein or peptide | Agonist | 12 |
| Pasireotide | Approved | Novartis Pharmaceuticals | Protein or peptide | Agonist | 8 |
| Vapreotide | Phase 3 | — | Protein or peptide | Agonist | 0 |
| Onzigolide | Phase 2 | Tiburio Therapeutics | Other | Agonist | 0 |
| Veldoreotide | Phase 2 | Aspireo Pharmaceuticals Limited | Protein or peptide | Agonist | 0 |
Open trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 16 in all, from ClinicalTrials.gov.Diseases most associated with it
Open Targets association score, 0 to 1; all associations- Acromegaly
- 0.61
- Neoplasm
- 0.58
- Neuroendocrine neoplasm
- 0.58
- Carcinoid tumor
- 0.52
- Carcinoid syndrome
- 0.49
- ACTH-dependent Cushing syndrome
- 0.48
- Neuroendocrine carcinoma
- 0.46
- Neurodegenerative disease
- 0.45
- Digestive system neuroendocrine tumor, grade 1/2
- 0.41
- Cancer
- 0.40
Genes and related targets
Complexes and families that share a gene with this target- Genes
- SSTR5
- Related
- Somatostatin receptor
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1792, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P35346, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets